Medical/Pharmaceuticals
FDA approves CartiHeal's Implant for the Treatment of Cartilage and Osteochondral Defects
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint KFAR SABA, Israel, March 30, 2022 /PRNewswire/...
2022-03-30 19:00
2108
Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication
--Compared to the placebo cohort, both 10 mg and 15 mg ASC42 cohorts are safe and well tolerated to date. Most of adverse events are grade 1 or 2. --ASC42 is a novel anti-viral candidate for HBV functional cure through inhibiting the transcription of HBV cccDNA into HBV RNA and reducing the HBV ...
2022-03-30 18:26
3497
BioVaxys Expands Cancer Vaccine Platform
BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC, March 30, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer vaccine platform with BVX-0922, its autolog...
2022-03-30 16:02
4746
Terumo and Glooko Announce Collaboration on New Solution for Diabetes Data Sharing
A Technology Integration for MEDISAFE WITHTM Insulin Patch Pump Patients to
Upload Data Anytime Anywhere
TOKYO, March 30, 2022 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a
global leader in medical technology, andGlooko
2022-03-30 15:00
6263
GILEAD ANNOUNCES NEW DATA REINFORCING CLINICAL BENEFITS OF ITS ANTIVIRAL TREATMENTS AMONG PEOPLE LIVING WITH HEPATITIS B AND C IN ASIA (APASL 2022)
* Studies show potential improvement in risk of liver cancer in chronic hepatitis B patients after long-term antiviral treatment * Improved renal and bone parameters with tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF) across multiple chronic hepatitis B patient t...
2022-03-30 11:00
2219
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights
SUZHOU, China, March 30, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2021 and highlighted recent progress and upcoming milestones. Highlights * First product launch: In November 2021, KN035 (Envafolimab) has receiv...
2022-03-30 10:36
2902
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights
SUZHOU, China, March 29, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2021 and highlighted recent progress and upcoming milestones. Highlights * First product launch: In November 2021, KN035 (Envafolimab) has receiv...
2022-03-30 10:35
2553
Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
* This study is the third ATG-016 study to be conducted in China. * Study highlights Antengene's robust SINE programs. SHANGHAI and HONG KONG, March 30, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutic...
2022-03-30 09:00
3738
RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
GAITHERSBURG, Md., March 30, 2022 /PRNewswire/ -- RNAimmune, Inc. (the "Company " or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximatelyUS$27 million Series A round of fina...
2022-03-30 08:31
3758
Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
DURHAM, N.C. and BEIJING, March 30, 2022 /PRNewswire/ -- Brii Biosciences
Limited
2022-03-30 08:05
4470
Innovent Announced 2021 Annual Results
* A Harvest Year with Product Revenue over RMB 4Bn * A Pipeline of 32 Valuable Assets with Late Stage Pipeline Potential Unveiling SAN FRANCISCO and SUZHOU, China, March 30, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that de...
2022-03-30 08:00
5387
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
SHANGHAI, March 30, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) reported positive topline results from a second Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) ...
2022-03-30 08:00
4458
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology
- Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody - Biosion earns a $10 million upfront license fee; additional milestone payments and royalties on commercial sales to be earned up...
2022-03-29 23:00
2889
MedTech Baymatob completes capital raise to advance life-saving labor monitoring device
SYDNEY, March 29, 2022 /PRNewswire/ -- Medical device company Baymatob has completed a placement ofA$4.215 million, with proceeds used to continue in-human clinical trials for its AI-guided labor monitoring device, Oli. Cornerstoned by Australian Unity's Future of Healthcare Fund, the placement ...
2022-03-29 21:34
2437
CellOrigin Closed a New Round of Investment to Jump-start its iPSC Immune Cell Therapy Products Toward Clinics
HANGZHOU, China, March 29, 2022 /PRNewswire/ -- On Mar.21, 2022, CellOrigin Inc, a biotech company focusing on iPSC-derived immune cell therapies, announced it secured a new round of investment of ~100 million RMB from Jifeng Ventures, Kunlun Capital, Yinxinggu Capital and Efung Capital. CellOri...
2022-03-29 20:50
2234
Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board
SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage global biotechnology company，announced today the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board (SAB). Dr. Porter has over 25 years of global R&D leadership and strat...
2022-03-29 20:00
2140
New Video Series "PSMA PET/CT TODAY" Discusses the Future of Prostate Cancer Care with Leading Experts
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the launch of PSMA PET/CT[1] Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in pr...
2022-03-29 19:00
2339
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
* Financial results demonstrate strong fundamentals * Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab * Seven business development deals, including a US$315M strategic commercial partnership with Jumpcan on...
2022-03-29 18:10
3504
Nippon Express (Middle East) Becomes First Japanese Logistics Company to Acquire GDP Certification in Middle East
TOKYO, March 29, 2022 /PRNewswire/ -- Nippon Express (Middle East) L.L.C. (hereinafter "NX Middle East"), a group company of Nippon Express Holdings, Inc., onFebruary 3, 2022, became the first Japanese logistics company in the Middle East to obtain Good Distribution Practice (GDP) certification f...
2022-03-29 14:00
1917
Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for TLX66 (90Y-besilesomab), for conditioning trea...
2022-03-29 13:34
2740
Week's Top Stories
Most Reposted
/C O R R E C T I O N - Autodesk, Inc./
[Picked up by 1321 media titles]
2026-10-29 01:23
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1167 media titles]
2026-11-02 20:00Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
[Picked up by 1148 media titles]
2026-10-28 20:30Piramal Pharma Limited Announces Results for Q2 and H1 FY27
[Picked up by 1084 media titles]
2026-10-28 03:28Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
58123
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
52850
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
51202
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
20636
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
15883